Literature DB >> 22147588

Destructive role of myeloid differentiation factor 88 and protective role of TRIF in interleukin-17-dependent arthritis in mice.

Shahla Abdollahi-Roodsaz1, Fons A J van de Loo, Marije I Koenders, Monique M Helsen, Birgitte Walgreen, Liduine A van den Bersselaar, Onno J Arntz, Nozomi Takahashi, Leo A B Joosten, Wim B van den Berg.   

Abstract

OBJECTIVE: Increasing evidence indicates the involvement of Toll-like receptors (TLRs) in the progression of arthritis; however, the contribution of the two signaling pathways used by TLRs, which are mediated by myeloid differentiation factor 88 (MyD88) and TRIF, remains unclear. The objective of this study was to investigate the specific roles of MyD88 and TRIF in chronic experimental arthritis and the accompanying adaptive immune responses.
METHODS: Chronic arthritis was induced in wild-type, MyD88(-/-) , and Trif(lps2) (TRIF(-/-) ) mice by repetitive intraarticular injections of streptococcal cell wall (SCW) fragments. SCW-specific T cell and B cell responses, joint swelling, and histopathologic changes were analyzed during chronic arthritis.
RESULTS: Both MyD88 and TRIF pathways contributed to antigen-specific T cell proliferation and antibody production, with the MyD88 pathway playing the dominant role. The severity of joint swelling and synovial inflammation, as well as the histopathologic damage to cartilage and bone, was strongly dependent on MyD88 signaling, whereas TRIF was redundant. MyD88 signaling was critical for the development of pathogenic T cell response (i.e., interleukin-17 [IL-17] production) in response to SCW antigen. Interestingly, when the T cell-dependent phase was prolonged, TRIF signaling appeared to down-regulate bone erosion, an effect accompanied by an inhibitory effect on IL-17 production.
CONCLUSION: This study reveals a central role of MyD88 and a counterregulatory function of TRIF in T cell-driven arthritis. The findings provide a rationale for a pathway-specific interference in order to block the pathogenic features and to preserve or stimulate the beneficial aspects of TLR signaling.
Copyright © 2012 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22147588     DOI: 10.1002/art.34328

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  9 in total

Review 1.  Toll-like receptors and chronic inflammation in rheumatic diseases: new developments.

Authors:  Leo A B Joosten; Shahla Abdollahi-Roodsaz; Charles A Dinarello; Luke O'Neill; Mihai G Netea
Journal:  Nat Rev Rheumatol       Date:  2016-05-12       Impact factor: 20.543

Review 2.  Pathways for bone loss in inflammatory disease.

Authors:  Tobias Braun; Georg Schett
Journal:  Curr Osteoporos Rep       Date:  2012-06       Impact factor: 5.096

3.  Toll-like receptor adaptor signaling molecule MyD88 on intervertebral disk homeostasis: in vitro, ex vivo studies.

Authors:  Michael B Ellman; Jae-Sung Kim; Howard S An; Di Chen; Ranjan KC; Jennifer An; Teju Dittakavi; Andre J van Wijnen; Gabriella Cs-Szabo; Xin Li; Guozhi Xiao; Steven An; Su-Gwan Kim; Hee-Jeong Im
Journal:  Gene       Date:  2012-06-10       Impact factor: 3.688

Review 4.  Immunogenetic control of the intestinal microbiota.

Authors:  Eric Marietta; Abdul Rishi; Veena Taneja
Journal:  Immunology       Date:  2015-06-03       Impact factor: 7.397

5.  The deubiquitinase A20 mediates feedback inhibition of interleukin-17 receptor signaling.

Authors:  Abhishek V Garg; Mushtaq Ahmed; Abbe N Vallejo; Averil Ma; Sarah L Gaffen
Journal:  Sci Signal       Date:  2013-06-04       Impact factor: 8.192

Review 6.  Synovium and the innate inflammatory network in osteoarthritis progression.

Authors:  Ru Liu-Bryan
Journal:  Curr Rheumatol Rep       Date:  2013-05       Impact factor: 4.592

7.  Targeting MyD88 Downregulates Inflammatory Mediators and Pathogenic Processes in PBMC From DMARDs-Naïve Rheumatoid Arthritis Patients.

Authors:  Sergio Ramirez-Perez; Edith Oregon-Romero; Itzel Viridiana Reyes-Perez; Pallavi Bhattaram
Journal:  Front Pharmacol       Date:  2021-12-23       Impact factor: 5.810

8.  The involvement of Toll-like receptor 9 in the pathogenesis of erosive autoimmune arthritis.

Authors:  Anita Fischer; Shahla Abdollahi-Roodsaz; Christina Böhm; Birgit Niederreiter; Brigitte Meyer; Anthony C Y Yau; Erik Lönnblom; Leo A B Joosten; Marije Koenders; Christian H K Lehmann; Diana Dudziak; Gerhard Krönke; Rikard Holmdahl; Günter Steiner
Journal:  J Cell Mol Med       Date:  2018-07-11       Impact factor: 5.310

9.  Designing anti-inflammatory drugs from parasitic worms: a synthetic small molecule analogue of the Acanthocheilonema viteae product ES-62 prevents development of collagen-induced arthritis.

Authors:  Lamyaa Al-Riyami; Miguel A Pineda; Justyna Rzepecka; Judith K Huggan; Abedawn I Khalaf; Colin J Suckling; Fraser J Scott; David T Rodgers; Margaret M Harnett; William Harnett
Journal:  J Med Chem       Date:  2013-11-25       Impact factor: 7.446

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.